Compliant, consistent and transferrable techniques for viral vector characterization and monitoring
Emerging modalities, like viral vectors, represent part of one of the fastest growing therapeutic segments, gene therapy, and they are transforming patient lives through cures for diseases and more recently addressing the COVID-19 pandemic. The complexity of this nascent class of therapies is linked to their own complexity and the limited precedence. This presentation will describe how learnings from traditional biopharmaceuticals can be applied to this new area.
Join Dr. Colette Quinn as she shares compliant, consistent and transferrable techniques for viral vector characterization and monitoring.
Key learning objectives:
- Growth and optimism supporting viral vector therapies and vaccines
- How compliant methods from protein characterization can be ported over into this space
- Techniques for getting more consistent results
Who should attend:
- Biopharma organizations, CXO and research institutes
- Analytical scientists supporting biologics development, R&D, BMR discovery, structural biology, higher-order structure analysis
- Lab managers, directors and VPs in charge of protein characterization, structural biologist
Presenter: Dr. Colette Quinn (Senior business development manager, biopharmaceutical global marketing, Waters Corporation)
Colette Quinn, Ph.D., is a Sr. business development manager in the biopharmaceutical global marketing team. Prior to joining Waters Corporation in 2010 she received her doctorate from Dartmouth College in chemistry with a focus in biophysical techniques.
Moderator: Sarah Thomas (Editorial Team, SelectScience)
Sarah studied biology at the University of Bath, UK, and has worked in the Pharmaceutical Sciences Department of St. Jude Children’s Research Hospital, Memphis. As a member of the Editorial team, Sarah plays an integral role in shaping the content on SelectScience.
